Industry Vet Todd Zavodnick Joins Dermavent Sciences as CEO

Todd Zavodnick is the new Chief Executive Officer of Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences.

"It is an honor to join Dermavant at such an exciting time in the company's growth," says Mr. Zavodnick in a news release. "Medical dermatology is a therapeutic area in need of real innovation, and that is precisely what we intend to provide at Dermavant."

Mr. Zavodnick has more than 20 years of leadership experience in the biopharmaceutical industry. He joins Dermavant from Revance, a biotechnology company where he served as Chief Commercial Officer and President of Aesthetics and Therapeutics. He previously served in global leadership roles at ZELTIQ Aesthetics prior to the company's acquisition by Allergan, at Galderma Laboratories where he was president and general manager of North America and responsible for a portfolio of products generating more than $1 billion in annual sales, and at Alcon Laboratories.

"We are thrilled to have Todd join Dermavant as we prepare to initiate our Phase 3 program for tapinarof," says Frank Torti, MD, Vant Investment Chair for Roivant Pharma and Chairman of the Board for Dermavant. "Todd's deep expertise in dermatology will help Dermavant deliver innovative therapies to health care providers and patients worldwide."

Mr. Zavodnick holds a Master of Business Administration from The University of Texas at Dallas and a Bachelor of Science in Pharmacy from Rutgers University. He is a member of the board of directors of the Children's Skin Disease Foundation.